)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
NanoEcho
NanoEcho (NANECH) investor relations material
NanoEcho Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary25 Aug, 2026
Executive summary
Achieved first commercial system sale, generating initial revenues and validating operational capabilities.
Continued clinical validation of diagnostic system, with focus on proof-of-concept studies and system improvements.
Maintained high activity despite financial constraints, implementing targeted cost savings and efficiency measures.
Patent portfolio strengthened with new US design patent approval.
Financial highlights
Q2 2026 net sales reached 488 TSEK, compared to 0 TSEK in Q2 2025, driven by first system sale.
Net loss after tax for Q2 2026 was -3,499 TSEK, improved from -4,512 TSEK in Q2 2025.
Cash flow from operations for Q2 2026 was -3,613 TSEK, compared to -3,817 TSEK in Q2 2025.
Cash and cash equivalents at period end were 533 TSEK, down from 8,672 TSEK a year earlier.
Equity at period end was 14,138 TSEK, with a solid equity ratio of 79%.
Outlook and guidance
Focus remains on clinical validation, market approval, and commercialization, with plans to submit for market approval by 2029, contingent on securing necessary capital.
Short-term and long-term financial situation remains strained; ongoing efforts to secure bridge and long-term financing.
Updated EIC Accelerator grant application submitted, with next evaluation step in September.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from NanoEcho
- First commercial sale achieved, net loss -5.2 MSEK, and market approval delayed to H2 2029.NANECH
Q1 2026 - First commercial sale and clinical milestones achieved, with continued financial losses and new funding.NANECHQ4 2025
- First commercial sale and improved financials mark progress toward clinical and market milestones.NANECHQ3 2025
- Clinical milestones reached, losses narrowed, and first revenues expected soon.NANECHQ2 2025
- Strong equity and clinical progress position NanoEcho for future commercialization.NANECHQ3 2024
- Product development finalized, ISO certified, and clinical phase initiated after successful financing.NANECHQ2 2024
- Clinical milestone achieved and financial base strengthened for rectal cancer diagnostics.NANECHQ1 2025
- Clinical progress, new financing, and IPO recognition mark NanoEcho's pivotal year.NANECHQ4 2024
Next NanoEcho earnings date
Q4 202622 Feb, 2027
NanoEcho
Next NanoEcho earnings date
Q4 202622 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
NanoEcho is a Swedish medical technology company specializing in the development of diagnostic imaging solutions focused on cancer detection. The company is developing an advanced imaging system using magnetic nanoparticles to enhance the accuracy of detecting cancerous tissues, particularly for rectal cancer diagnostics. NanoEcho’s technology aims to provide non-invasive, precise imaging to improve diagnostic outcomes and patient care. Targeting healthcare providers, the company’s innovations are designed to aid in early cancer detection and streamline the diagnostic process. NanoEcho is headquartered in Lund, Sweden, and its shares are listed on the Stockholm Stock Exchange.